JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions
Madrigal Pharmaceuticals used its January 12 presentation at the J.P. Morgan Healthcare Conference 2026 to showcase its newly acquired assets…
Cardiovascular
-
-
JPM26: Pfizer’s Metsera deal supercharges its obesity strategy
Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the…
-
AHA 2025: semaglutide 2.4mg lowers cardiovascular risk in SCORE-HF Study
On 10 November at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, data from the SCORE-HF…
-
Affinia raises $40m for gene therapy development
Gene therapy company Affinia Therapeutics has raised $40m in a Series C funding round, led by New Enterprise Associates (NEA).…
-
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug…
-
Mabwell and Aditum launch Kalexo Bio for siRNA therapy development
China’s Mabwell Bioscience and US-based Aditum Bio have launched Kalexo Bio, a new company, to develop a new small interfering…
-
Podcast: key trials and trends from ESC Congress 2025
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to…
-
Hengrui Pharma signs deal with Braveheart Bio for HRS-1893
Hengrui Pharma has agreed with US-based Braveheart Bio, which specialises in cardiovascular diseases, granting it an exclusive licence for its…
-
Novartis adds again to siRNA pipeline with second deal in a day
Novartis has secured a licensing agreement with China-based Argo Biopharma just after signing a contract with Arrowhead, marking two small…
-
ESC 2025: Novo Nordisk’s Wegovy superior to Zepbound in reducing CV events
Novo Nordisk’s glucagon-like peptide-1 receptor agonist (GLP-1RA) Wegovy (semaglutide) showed a significant reduction in cardiovascular (CV) events compared to Eli…
